Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | ARV-825 |
Synonyms | |
Therapy Description |
ARV-825 is a heterobifunctional PROTAC (Proteolysis Targeting Chimera) compound that links OTX015 to Pomalyst (pomalidomide), which targets BRD4 for degradation in a proteosome dependent manner, potentially leading to downregulation of cMyc, decreased proliferation, and increased apoptosis in cancer cells (PMID: 26051217). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ARV-825 | ARV825|ARV 825 | BRD4 Inhibitor 9 | ARV-825 is a heterobifunctional PROTAC (Proteolysis Targeting Chimera) compound that links OTX015 to Pomalyst (pomalidomide), which targets BRD4 for degradation in a proteosome dependent manner, potentially leading to downregulation of cMyc, decreased proliferation, and increased apoptosis in cancer cells (PMID: 26051217). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|